文献速递系统性红斑狼疮

累积免疫抑制剂暴露与系统性红斑狼疮患者多样化癌症风险的关联:一项嵌套病例对照研究

Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究基于台湾全民健康保险研究数据库,纳入2001至2013年14 842例系统性红斑狼疮(SLE)患者,采用回顾性嵌套病例对照设计,比较合并后期癌症与无癌症患者的免疫抑制剂累积剂量。匹配后纳入330例癌症患者和1320例无癌症对照,调整分析显示较高的环磷酰胺(CYC)累积剂量(OR=1.09,95%CI:1.04,1.13)和较低的羟氯喹(HCQ)剂量(OR=0.93,95%CI:0.90,0.97)与癌症风险相关。结论认为不同免疫抑制剂与SLE患者不同癌症风险相关,CYC增加癌症风险而HCQ降低癌症风险,均呈剂量依赖性。

要点

  • 较高累积环磷酰胺剂量与SLE患者癌症风险升高相关(OR=1.09,95%CI:1.04,1.13)。
  • 较低累积羟氯喹剂量与SLE患者癌症风险升高相关(OR=0.93,95%CI:0.90,0.97)。
  • CYC增加癌症风险、HCQ降低癌症风险均呈剂量依赖性。

核心结论

  • 不同免疫抑制剂与SLE患者不同癌症风险相关,CYC增加癌症风险而HCQ降低癌症风险,均呈剂量依赖性。

研究设计与样本

  • 基于台湾全民健康保险研究数据库的回顾性嵌套病例对照研究,筛查2001至2013年14 842例SLE患者,匹配后纳入330例癌症患者和1320例无癌症对照。

主要发现

  • 癌症类型前五位为乳腺癌(16.9%)、血液系统癌(11.7%)、结直肠癌(11.0%)、肺癌(10.6%)和肝胆癌(10.4%)。
  • 调整分析显示较高累积CYC剂量(OR=1.09,95%CI:1.04,1.13)与癌症风险相关。
  • 调整分析显示较低累积HCQ剂量(OR=0.93,95%CI:0.90,0.97)与癌症风险相关。

关键数值与推荐

  • 免疫抑制剂累积剂量从SLE诊断日期计算至癌症发生,关注药物包括AZA、CYC、MTX、HCQ和全身性糖皮质激素。
  • 癌症调整比值比(OR)在倾向评分匹配后通过条件Cox回归模型计算。

临床怎么用

  • 在SLE长期管理中应关注免疫抑制剂的累积剂量,尤其是CYC的癌症风险并重视HCQ的潜在保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immunosuppressive therapy is necessary to alter the natural course of SLE. However, immunosuppressant-related cancer risk is a major concern. The aim of this study was to determine whether immunosuppressant use is associated with cancer risk in SLE. METHODS: We designed a retrospective nested case-control study within an SLE population based on the National Health Insurance Research Database in Taiwan. We screened 14 842 patients with SLE from 2001 to 2013 and compared patients with SLE complicated by later cancer with patients with SLE but without cancer. The cumulative dose of immunosuppressants was calculated from the SLE diagnosis date to the occurrence of cancer. The immunosuppressants of interest were AZA, CYC, MTX, HCQ and systemic glucocorticoids. Adjusted odds ratios (ORs) for cancer were calculated in conditional Cox regression models after propensity score matching. RESULTS: The top five types of cancers were breast (16.9%), haematological (11.7%), colorectal (11.0%), lung (10.6%) and hepatobiliary (10.4%) cancers. After matching, this study included 330 cancer patients and 1320 matched cancer-free patients. The adjusted analyses showed an association of a higher cumulative CYC dose (OR = 1.09, 95% CI: 1.04, 1.13) and lower HCQ dose (OR = 0.93, 95% CI: 0.90, 0.97) with cancer risk in comparison with the controls. CONCLUSION: Diverse cancer risks are associated with different immunosuppressants in patients with SLE. CYC increases the risk of cancer, and HCQ decreases this risk in SLE patients, both in a dose-dependent manner.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hsu CY, Lin MS, Su YJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017. PMID: 28039419. doi:10.1093/rheumatology/kew457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。